N

Ningbo Menovo Pharmaceutical Co Ltd
SSE:603538

Watchlist Manager
Ningbo Menovo Pharmaceutical Co Ltd
SSE:603538
Watchlist
Price: 13.6 CNY 1.72% Market Closed
Market Cap: 2.9B CNY
Have any thoughts about
Ningbo Menovo Pharmaceutical Co Ltd?
Write Note

Ningbo Menovo Pharmaceutical Co Ltd
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Ningbo Menovo Pharmaceutical Co Ltd
Capital Expenditures Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
N
Ningbo Menovo Pharmaceutical Co Ltd
SSE:603538
Capital Expenditures
-ÂĄ219.5m
CAGR 3-Years
11%
CAGR 5-Years
6%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Capital Expenditures
-ÂĄ219.6m
CAGR 3-Years
46%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Capital Expenditures
-ÂĄ103.9m
CAGR 3-Years
37%
CAGR 5-Years
-6%
CAGR 10-Years
4%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Capital Expenditures
-ÂĄ1.6B
CAGR 3-Years
-3%
CAGR 5-Years
-27%
CAGR 10-Years
-23%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Capital Expenditures
-ÂĄ548.5m
CAGR 3-Years
1%
CAGR 5-Years
6%
CAGR 10-Years
-27%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Capital Expenditures
-ÂĄ81.9m
CAGR 3-Years
-75%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Ningbo Menovo Pharmaceutical Co Ltd
Glance View

Market Cap
3B CNY
Industry
Pharmaceuticals

Ningbo Menovo Pharmaceutical Co., Ltd. engages in the research, development, testing, production, and sale of pharmaceutical products. The company is headquartered in Ningbo, Zhejiang and currently employs 2,473 full-time employees. The company went IPO on 2017-04-07. The Company’s products contain gastropathic medicine and cardiovascular medicine, which include anti-hypertension medicine, anti-hyperlipidemia medicine and anti-thrombus medicine. The firm distributes its products to both domestic and overseas markets.

Intrinsic Value
13.33 CNY
Overvaluation 2%
Intrinsic Value
Price
N

See Also

What is Ningbo Menovo Pharmaceutical Co Ltd's Capital Expenditures?
Capital Expenditures
-219.5m CNY

Based on the financial report for Dec 31, 2023, Ningbo Menovo Pharmaceutical Co Ltd's Capital Expenditures amounts to -219.5m CNY.

What is Ningbo Menovo Pharmaceutical Co Ltd's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
6%

Over the last year, the Capital Expenditures growth was 62%. The average annual Capital Expenditures growth rates for Ningbo Menovo Pharmaceutical Co Ltd have been 11% over the past three years , 6% over the past five years .

Back to Top